DFDA

Prostaglandin E1 (Alprostadil) Infusion

Treatment for Congenital Heart Anomalies

Typical Dosage: 0.05-0.1 mcg/kg/min continuous IV infusion

Effectiveness
98%
Safety Score
40%
Clinical Trials
1
Participants
10K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
0.05-0.1 mcg/kg/min continuous IV infusion
Time to Effect
Minutes to hours
Treatment Duration
Hours to days (until surgical/catheter intervention)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Confidence Score
99%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$10,000
Side Effect Mgmt:$1,000
Total Annual:$16,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$5,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$16,326.53
Prostaglandin E1 (Alprostadil) Infusion Outcomes

for Congenital Heart Anomalies

Efficacy Outcomes
Overall Effectiveness
+98%
Response Rate
+98%
Common Side Effects
Apnea
+10%
Fever
+10%
Hypotension
+5%
Flushing
+5%
Bradycardia
+2%
Seizures
+1%
Edema
+5%

Sources:

nih.gov
wikipedia.org
semanticscholar.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov